Discovery Of Small Molecules Which Drive Mhc Presentation Of Oncogene Derived Neoantigens
Invention Novelty
The invention describes a platform technology that increases MHC presentation of oncogene derived peptide neoantigens that do not normally occur in the cell. The platform has already been used to identify a method of increasing KRAS G12 D/V derived peptide presentation on MHC- I.
Value Proposition
The invention provides a platform to screen computationally and experimentally for a cell's ability to present cancer neoantigens.
The technology provides a strategy to enhance antigen presentation and bring intracellular oncogenes to the cell surface so that they are visible by T-cell surveillance.
The technology provides a new dimension of therapeutic intervention for cancer as it expands the repertoire of epitopes targetable by small molecules and/or immunotherapy.
Targeting driver oncogenes in adventageous because it is cancer specific and is essential for cancer growth.Patent Status
| Country | Type | Number | Dated | Case |
| European Patent Office | Published Application | EP4081254 | 11/02/2022 | 2020-070 |
Additional Patents Pending
Contact
- Catherine Smith
- Catherine.Smith2@ucsf.edu
- tel: View Phone Number.
Other Information
Keywords
Oncogene-derived neoantigen, MHC presentation, small molecule